
    
      INSPIRE, the largest and most comprehensive clinical trial ever conducted in IPF, has now
      completed enrolling patients with mild to moderate IPF. Eligible patients will receive either
      Interferon gamma-1b or placebo for a minimum of 2 years.
    
  